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ABSTRACT
We assessed population-based trends in incidence and
survival rates for epithelial ovarian cancer in Ontario
in two time periods. Our population-based study co-
hort included all women with epithelial ovarian can-
cer treated initially with abdominal surgery in Ontario
for January 1996 through December 2001. Incident
surgical cases were documented by hospital contact
data and the Ontario Cancer Registry. Patient charac-
teristics (age, for example) were obtained from elec-
tronic administrative data records. Regression analyses
were used to assess the influence of time period on
survival while controlling for age, comorbidity, and
other factors associated with this outcome.
A total of 3825 women met the inclusion criteria.
We found that the age-standardized incidence of ova-
rian cancer remained stable during 1996–2001. A shift
to a younger age at diagnosis was found between the
two time periods being compared. The univariate analy-
sis revealed a clear difference in death rate, to which
age at diagnosis, Charlson comorbidity score, and treat-
ment period contributed. Earlier time period (p <
0.0001), advancing age (p < 0.0001), higher Charlson
score (p < 0.0001), and lower income quartile score
(p = 0.03) were significantly associated with poorer sur-
vival in the univariate analysis. Younger age, lower
Charlson score, and more recent time period of diag-
nosis and treatment (p < 0.0001) were associated with
improved survival in the proportional hazards model.
We conclude that age-standardized incidence and
mortality rates for ovarian cancer in Ontario have re-
mained stable. For women initially treated with sur-
gery, advances in management have led to an
improvement in survival.
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1. INTRODUCTION
Ovarian cancer is the leading cause of gynecologic
cancer death in women. Management involves a com-
bination of surgery and adjuvant chemotherapy. Sur-
gery is important for making the diagnosis, identify-
ing prognostic factors, alleviating symptoms, and
extending survival. Adjuvant chemotherapy usually
involves a combination of platinum and taxanes 1.
In 2005, we reviewed outcomes in women who
had received chemotherapy for ovarian cancer dur-
ing 1995–2002 2. We showed that provider discipline
and provider’s volume of ovarian cancer chemo-
therapy cases did not affect patient survival. In that
work, we noted a trend toward improved survival for
the later period of study. In that paper, we suggested
that advances in systemic therapy were likely respon-
sible for the observed trend.
The objective of the present study was to ana-
lyze and compare trends in the incidence and sur-
vival rates for epithelial ovarian cancer among women
who received surgery as initial treatment (with or
without adjuvant chemotherapy) during 1996–1998
and 1999–2001. Factors that could influence survival
rates were assessed.
2. PATIENTS AND METHODS
2.1 Data Sources and Elements
Our population-based cohort study included all women
with newly diagnosed ovarian cancer treated initially
with abdominal surgery in Ontario from January 1,
1996, to December 31, 2001. The Canadian Institute
for Health Information (CIHI) program gathers all hos-
pital discharge data. The Ontario Cancer Registry (OCR)
gathers all malignant histology information related to
patients as provided by all Ontario hospital and outpa-
tient laboratories. The CIHI and OCR data were used to
identify patients with ovarian cancer (International
Classification of Disease code 10, diagnostic code 183).
The CIHI records identified 5240 ovarian cancer
patients in the study period. Of these, 1415 were ex-
cluded based on a prior ovarian cancer diagnosis be-
tween 1988 and December 31, 1995 (n = 18), age
less than 18 years (n = 10), surgery completed out of
province (n < 5), histology showing low malignant
potential disease or other non-epithelial tumour types
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(n = 1372), or index ovarian cancer surgery occur-
ring before January 1, 1996, or after December 31,
2001. The study database consisted of 3825 incident
cases that were identified for 1996–2001 in the OCR
by a process of case ascertainment consisting of de-
terministic linkage of records from the cancer cen-
tres, pathology reports from the Ontario hospitals,
hospital discharge abstracts from CIHI, and death cer-
tificates from the registrar general.
Information concerning mortality (death from any
cause after the diagnosis with ovarian cancer) was
obtained from the Registered Persons Database of
the Ontario Health Insurance Program, the OCR, and
the CIHI. Survival follow-up was complete to March
2006, resulting in total follow-up times ranging from
1 day to 10.4 years. Dates of birth and diagnosis were
obtained from the OCR and the CIHI. Comorbidity was
documented from CIHI diagnosis codes using the
Charlson–Deyo comorbidity score 3.
Ontario is divided into 14 local health integrated
networks (LHINs) that implement a regional approach
to planning, integrating, and funding local health ser-
vices. Regional residence of patients (by LHIN) was
examined as having a potential influence on survival,
as were quintiles of household income by location of
the patients’ residences, as assigned from Canadian
census data matched to the postal code of each
patient’s residence.
Analysis of data on survival time used the
Kaplan–Meier estimation of survival functions and
log-rank tests for unadjusted survival time compari-
sons. The Cox proportional hazards model was used
to assess the significance of differences in mortality
rates between time periods, adjusting for differences
in other predictors of survival between the two time
periods. Model diagnostics included assessment of
assumptions of the Cox model.
3. RESULTS
In Ontario, the average number of patients receiving
initial surgery for treatment of their epithelial ova-
rian cancer ranged from a low of 588 cases in calen-
dar year 1997 to a high of 708 cases in 2001. The
age-standardized incidence of epithelial ovarian can-
cer in Ontario was 14 per 100,000 woman–years in
both 1996 4 and 2001 5. This incidence is slightly
higher than that reported in Canada in 1996 4 (13 per
100,000) and in 2001 5 (12 per 100,000).
3.1 Deaths and Proportion Deceased
Table I presents numbers of patients and observed
deaths in the period of follow-up by time period and
patient characteristics. Across the two time periods,
2356 deaths were observed (61.6% of the cohort).
Using chi-square analysis, the age distribution (p =
0.0002)—but not the Charlson comorbidity score (p =
–0.86), income quintile (p = –0.45), or LHIN (p =
0.38)—was observed to be different between the two
time periods. The average number of ovarian cancer
patients per region (LHIN) ranged from 61 to 429 over
the 6-year period (data by LHIN not shown because of
small numbers and confidentiality concerns).
Death rates were higher in the earlier time period
(attributable to longer follow-up). The crude propor-
tion of deaths was also higher among patients with
more advanced age and higher Charlson comorbid-
ity score at diagnosis (Table II). In Ontario, with its
socialized medical care system, income quintile and
LHIN of residence were not associated with mortality.
3.2 Duration of Survival
Univariate analysis by the log-rank test or unadjusted
Cox model for survival, using days to death, showed
that the earlier time period, advancing age, higher
Charlson score, and lower income quintile scores
were each statistically significantly associated with a
lower duration of survival (Tables III and IV). Where
a patient lived in Ontario (LHIN) did not affect dura-
tion of survival; however, the median duration of
survival was lowest in the LHIN with the lowest num-
ber of cases (that is, in a less densely populated re-
gion). The proportional hazards regression model
showed that age, Charlson score, and time period for
treatment all affected survival (p < 0.0001; Table V).
After consideration of differences in patient age and
comorbidity between the two time periods, expected
patient survival was improved in 1999–2001 as com-
pared with 1996–1998. In the more recent period, pa-
tients were experiencing 90% of the mortality observed
in the earlier time period per follow-up time unit.
TABLE I Patient characteristics, 1996–2001 a
1996–1998 1999–2001 Overall
[n (%)] [n (%)] [n (%)]
Patients 1852 1973 3825
Age (years)
18–49 409 (22.1) 488 (24.7) 897 (23.5)
50–59 396 (21.4) 508 (25.8) 904 (23.6)
60–69 486 (26.2) 457 (23.2) 943 (24.7)
70+ 561 (30.3) 520 (26.4) 1081 (28.3)
CCI
0 577 (31.2) 680 (34.5) 1257 (32.9)
1–5 347 (18.7) 361 (18.3) 708 (18.5)
³6 928 (50.1) 932 (47.2) 1860 (48.6)
Income quintile
1 356 (19.9) 339 (17.6) 695 (18.7)
2 361 (20.1) 405 (21.0) 766 (20.6)
3 354 (19.7) 405 (21.0) 759 (20.4)
4 334 (18.6) 365 (18.9) 699 (18.8)
5 388 (21.6) 415 (21.5) 803 (21.6)
NA 59 44 103
a Because of rounding, category percentages may not add to ex-
actly 100.
CCI = Charlson Comorbidity Index.OVARIAN CANCER TRENDS IN ONTARIO
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4. DISCUSSION
Our analysis demonstrates that patient survival after
epithelial ovarian cancer was significantly improved
in 1999–2001 as compared to that observed in 1996–
1998. Our analysis also confirms the importance to
survival of comorbidity and age at diagnosis. We
observed a shift toward a younger age at diagnosis
between the two time periods, but that difference did
not explain the improvement in survival.
In a socialized health care system, income strata
and geographic region of residence did not affect the
death rate. In the univariate analysis, duration of sur-
vival was associated with age, Charlson comorbidity
score, income quintile, and treatment period. How-
ever, only treatment period, age, and Charlson score
were important in the regression model. Despite an
almost doubling of the age-standardized incidence
of ovarian cancer, advances in management have led
to an improvement in survival.
TABLE V Univariate analysis of duration of survival (in days)
Covariate Patients Survival (days) p Value
(n) Mean SD Median
Period
1996–1998 1852 1534 1244 1164 <0.0001
1999–2001 1973 1248 787 1354
Age (years)
18–49 897 1690 1016 1721 <0.0001
50–59 904 1521 984 1516
60–69 943 1321 1037 1058
70+ 1081 1079 1031 693
CCI
0 1257 1970 976 2000 <0.0001
1–5 708 1525 1096 1543
³6 1860 939 837 683
Income quintile
1 695 1301 1059 1078 0.0274
2 766 1406 1065 1287
3 759 1336 1032 1136
4 699 1458 1035 1435
5 803 1419 1012 1385
LHIN 0.9303
SD = standard deviation; CCI = Charlson Comorbidity Index; LHIN =
local health integrated network.
TABLE IV Hazard ratio estimated by Cox regression model
Covariate Hazard 95% CI 95% CI p Value
ratio lower upper
Period
1999–2001 0.90 0.83 0.98 0.0146
1996–1998 Ref
Age (years)
18–49 Ref
50–59 1.39 1.22 1.59 <0.0001
60–69 1.75 1.54 1.99 <0.0001
70+ 2.40 2.13 2.72 <0.0001
CCI
0 Ref
1–5 0.79 0.71 0.89 <0.0001
³6 1.94 1.71 2.19 <0.0001
Ref = reference variable.
TABLE III Univariate analysis by death rate
Covariate Mortality rate Relative p Value
(%) risk
Period
1996–1998 67.2 1.19 <0.0001
1999–2001 56.4 1.00
Age (years)
18–49 43.5 1.00 <0.0001
50–59 57.1 1.31
60–69 66.5 1.53
70+ 76.1 1.75
CCI
0 33.4 1.00 <0.0001
1–5 53.0 1.59
³6 83.9 2.51
Income quintile
1 64.0 1.00 0.2025
2 60.6 0.95
3 63.6 0.99
4 59.1 0.92
5 60.1 0.94
LHIN a 0.5318
a Fourteen regions are not shown because of small numbers in some
cases.
CCI = Charlson Comorbidity Index; LHIN = local health integrated
network.
TABLE II Frequency distribution a of patients and deaths by demo-
graphic characteristics
1996–1998 1999–2001
Patient Deaths Patient Deaths
[n (%)] [n (%)] [n (%)] [n (%)]
Age (years)
18–49 409 (22.1) 200 (48.9) 488 (24.7) 190 (38.9)
50–59 396 (21.4) 251 (63.4) 508 (25.8) 265 (52.2)
60–69 486 (26.2) 347 (71.4) 457 (23.2) 280 (61.3)
70+ 561 (30.3) 446 (79.5) 520 (26.4) 377 (72.5)
CCI
0 577 (31.2) 208 (36.0) 680 (34.5) 212 (31.2)
1–5 347 (18.7) 209 (60.2) 361 (18.3) 166 (46.0)
6+ 928 (50.1) 827 (89.1) 932 (47.2) 734 (78.8)
Income quintile
1 356 (19.9) 249 (69.9) 339 (17.6) 196 (57.8)
2 361 (20.1) 233 (64.5) 405 (21.0) 231 (57.0)
3 354 (19.7) 240 (67.8) 405 (21.0) 234 (57.8)
4 334 (18.6) 218 (65.3) 365 (18.9) 195 (53.4)
5 388 (21.6) 263 (67.8) 415 (21.5) 220 (53.0)
a Because of rounding, category percentages may not add to ex-
actly 100.
CCI = Charlson Comorbidity Index.ELIT et al.
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The age-standardized mortality rates in Ontario for
epithelial ovarian cancer remained stable over the two
time periods. The observed rates accord with those re-
ported from other developed countries 6–9. The decline
in the death rate in women who had surgery as the ini-
tial step in their management and the improved dura-
tion of survival in the later time period reflect either the
earlier stage of diagnosis or improved treatment, or both.
Although screening for ovarian cancer is not ad-
vocated in Ontario, awareness is increasing among
family doctors and patients about the importance of
ultrasound and tumour markers such as cancer anti-
gen 125 for women with symptoms suggestive of ova-
rian masses. Prophylactic surgery is also available for
women with known BRCA1, BRCA2, or MSH2 muta-
tions. These manoeuvres provide the potential to iden-
tify the disease at an earlier stage. To determine if a
stage shift is occurring, the stages of disease between
the two time periods might have been compared. But
although stage information is available for the earlier
cohort, it is not available for the later cohort 10.
Although not observed directly in the present study,
improved standards of care for ovarian cancer are likely
to be the explanatory factor for the improved survival
seen in the study cohort from the more recent period.
During 1994–1995, cancer centres across Canada par-
ticipated in a randomized trial of platinum with either
cyclophosphamide or taxanes (National Cancer Insti-
tute of Canada trial OV10) 11. Results from that study
were published in 2000. Subsequently, in September
2001, Cancer Care Ontario’s Program in Evidence-
Based Care published a practice guideline making
platinum and taxanes first-line therapy for advanced
ovarian cancer 12. The use of platinum–taxane therapy
was increasing in Ontario before adoption of the guide-
line. With the training of an increased number of gy-
necologic oncologists in Ontario from the 1990s
onwards, a trend toward more aggressive surgical stag-
ing in early disease and tumour debulking for advanced
disease may also have been occurring, together with a
shift in referrals to gynecologic oncologists. Discipline
of the primary surgeon involved in the operation has
clearly been shown to affect survival.
The limitations of the present work include the lack
of detailed information in the most recent cohort for dis-
ease-related variables (for example, stage) and for treat-
ment (for example, chemotherapy agents used) 10. Thus,
our findings of survival benefit based on management
strategy are hypothesis-generating only. Age-standard-
ized incidence and mortality rates for ovarian cancer in
Ontario have remained stable. For women initially treated
with surgery, advances in management are likely to have
led to the observed improvement in survival.
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